EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized Clinical Trial

Theresia Monica Rahardjo, Hendra Subroto, Christian Adiutama, Aloysius Suryawan

Acta Medica Philippina · 14.04.2026

DOI: 10.47895/amp.vi0.13454 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Medica Philippina, online erschienen am 14.04.2026. Verfasst von Theresia Monica Rahardjo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Convalescent plasma therapy (CPT) has been utilized as an emergency and last-resort treatment for viral infections, particularly in the absence of vaccine. During the COVID-19 pandemic, CPT was implemented worldwide based on its potential to provide passive immunity through SARS-CoV-2 antibodies. While numerous studies explored the effectiveness of CPT to cure COVID-19 patients, there has no research specifically focused on superiority of CPT impact on the length of hospitalization.

Objective

This study aimed to evaluate the effect of CPT on the length of hospital stay among patients with moderate COVID-19.

Methods

This is a single blind randomized controlled trial (RCT) study involved 30 moderate-grade COVID-19 patients age 18-75 years with positive PCR result treated at Unggul Karsa Medika Hospital Bandung from February 2 to May 31, 2022. Moderate-grade COVID-19 defined by clinical pneumonia symptoms based on World Health Organization (WHO) criteria. Eligible patients were randomly assigned (1:1 ratio) and outcome assessors were blinded, while care providers and patients were not due to the intervention nature. The intervention arm (n=15) received 200 ml of high-titer CPT within 24 hours of admission with standard care and the control arm (n=15) received standard care only. The primary outcome measured was the length of stay (LOS) in both the Emergency Room (ER) and COVID-19 High Care Unit (HCU). Data were analyzed using independent T-tests.

Results

Thirty (30) eligible patients (mean age 40 years; 53% female) were analyzed for the primary outcome and all completed follow-ups. The CPT group had significantly shorter LOS than controls (mean difference for ER:-32.7 hours [95% CI:-45.0,-20.4]; HCU:-33.3 hours [95% CI:- 45.8,-20.8]; p

Schlagwörter

Stichwörter der Autor:innen

COVID-19antibodiesconvalescent plasma therapyhospitalizationlength of stay

Autor:innen und Institutionen

  • Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
  • Department of Clinical Pathology, Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
  • Medical Faculty Universitas Pendidikan Indonesia, Bandung, Indonesia.

Zitieren

APA

Rahardjo, T. M., Subroto, H., Adiutama, C., & Suryawan, A. (2026). The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized Clinical Trial. Acta Medica Philippina. https://doi.org/10.47895/amp.vi0.13454

Vancouver

Rahardjo TM, Subroto H, Adiutama C, Suryawan A. The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized Clinical Trial. Acta Medica Philippina. 2026. doi:10.47895/amp.vi0.13454

BibTeX
@article{Rahardjo2026,
  author = {Rahardjo, Theresia Monica and Subroto, Hendra and Adiutama, Christian and Suryawan, Aloysius},
  title = {The Value of Convalescent Plasma Therapy as a Strategy to Decrease Hospitalization in COVID-19 Patients: A Randomized Clinical Trial},
  journal = {Acta Medica Philippina},
  year = {2026},
  doi = {10.47895/amp.vi0.13454}
}
Kostenlos starten →